aDAPt-ANOCA: Dapagliflozin for the Treatment of Angina With Non-Obstructive Coronary Artery Disease (ANOCA)

Sponsor
The Christ Hospital
Study ID
NCT07741890
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Angina With Non-Obstructive Coronary Artery Disease
  • Coronary Microvascular Dysfunction (CMD)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin (10mg Tab) — DRUG
    The study will be double blinded by over encapsulation of Dapagliflozin with a matching lactose powder capsule used for the placebo group. All enrolled participants who meet inclusion / exclusion will receive either 10 mg Dapagliflozin (10mg) for 180 days, or placebo, randomized 1:1.
  • Placebo ( FE) — DRUG
    Over encapsulated placebo to match active drug.

Study Details

The primary purpose of this study is to evaluate the efficacy of DAPA for the treatment of coronary microvascular dysfunction (CMD) among patients with angina and no obstructive coronary artery disease (ANOCA) and established CMD as compared to placebo.

Key Dates

First listed
Aug 3, 2026
Start date
Sep 1, 2026
Status verified
Jul 2026
Primary completion
Dec 1, 2028
Completion
Mar 1, 2029

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin Arm
    Randomized to dapaflagozin 10 mg once daily for 180 days
  • Placebo Comparator: Placebo Arm
    Randomized to placebo once daily for 180 days

Primary Outcome Measure

Change in quantitative myocardial perfusion reserve index (MPRI) [ Time Frame: 180 days ]

Central Contacts

Related Studies